---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-025667"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2026-06-18T12:01:22+00:00"
generated_at: "2026-06-18T12:05:20.215109+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Grace Therapeutics FY2026 net loss $7.8M; FDA CRL for GTx-104; Type A meeting set

## Summary
- Net loss of $7.8M ($0.47 loss per share) for FY2026, improved from $9.6M loss in FY2025.
- Cash and equivalents $17.0M at March 31, 2026; expected to fund operations at least 12 months.
- FDA issued Complete Response Letter for GTx-104 NDA in April 2026; no clinical deficiencies cited; Type A meeting scheduled.
- Phase 3 STRIVE-ON trial met primary endpoint; 19% reduction in clinically significant hypotension vs oral nimodipine.
- New U.S. patent (No. 12,414,943) for IV dosing regimen extends GTx-104 IP protection to 2043.

## SEC filing metadata
- accession: 0001140361-26-025667
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2026-06-18T12:01:22+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000114036126025667/0001140361-26-025667-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000114036126025667/ef20076145_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-025667
- JSON: https://secwatch.observer/filing/0001140361-26-025667.json
- Plain text: https://secwatch.observer/filing/0001140361-26-025667.txt

## Key facts
- Earnings Releases
  Grace Therapeutics, Inc. reported the fiscal year ended March 31, 2026 results: net income net loss of $7.8 million, EPS $0.47 loss per share.
  - Period: the fiscal year ended March 31, 2026
  - Net income: net loss of $7.8 million
  - EPS: $0.47 loss per share
  - Result: reported results
  source text: The Company reported a net loss of $7.8 million, or $0.47 loss per share for the fiscal year ended March 31, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000114036126025667/0001140361-26-025667-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.